Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
2022; Massachusetts Medical Society; Volume: 386; Issue: 26 Linguagem: Inglês
10.1056/nejmoa2201817
ISSN1533-4406
AutoresMichael Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier Luigi Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, André Goy, Paul A. Hamlin, Olivier Hermine, José‐Ángel Hernández‐Rivas, Xiaonan Hong, Seok Jin Kim, David John Lewis, Yuko Mishima, Muhıt Özcan, Guilherme Fleury Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Steven Le Gouill, Martin Dreyling,
Tópico(s)Viral-associated cancers and disorders
ResumoIbrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.
Referência(s)